Replies to post #17228 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

not counting the “deferred revenue” line, which is not a true liability

It's not a true liability such as it owes that money to someone external to the company but it is a liability because it a charge against the asset side of the balance sheet.

If you decide to exclude or disregard it from the liability side it should equally be excluded from the asset side.

[DewDiligence]

MNTA’s 6/30/17 pro forma cash balance was $464.2M—a decrease of $6.7M relative to the $470.9M pro forma cash balance on 3/31/17 (#msg-131335614) .

The $464.4M figure consists of: $481.6M of current assets on the 6/30/17 balance sheet (https://www.sec.gov/Archives/edgar/data/1235010/000123501017000026/mnta2q201710-q.htm#sA04007A1C8AE5EA48D1B698ABCC39757 ); $10.3M of marketable securities designated as long-term (i.e. US Treasury bonds with a maturity >1yr); a $10M Glatopa milestone payment from NVS earned in 2Q17 (to be received in 3Q17); less $37.7M of liabilities (not counting the “deferred revenue” lines on the balance sheet, which are accounting artifacts rather than true liabilities).